The invention relates to compounds of formula I: ##STR00001##
where a, R.sup.1, and R.sup.3-6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin and norepinephrine reuptake inhibitors. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.

Provided herein are deuterated RUC-4 compounds, and related compositions and therapeutic methods.

Provided herein are deuterated RUC-4 compounds, and related compositions and therapeutic methods.

Described herein are methods for treating preterm labor, stopping labor prior to Cesarean delivery, preventing preterm labor, or controlling the timing of parturition by administering a chemical compound, such as a muscarinic receptor antagonist preferably a M, receptor antagonist, or a β-3 adrenergic agonist. Also described are methods for treating preterm labor, stopping labor preparatory to Cesarean delivers', preventing preterm labor, or controlling the timing of parturition by administering an effective amount of transdermal stimulation, posterior tibial nerve stimulation or another form of non-invasive or invasive neuromodulation, unstimulated or stimulated acupuncture, magnetic field therapy, or vibratory stimulation. These methods may be practiced individually, in combination with each other, or in combination with known tocolytic methods or medications.

Described herein are methods for treating preterm labor, stopping labor prior to Cesarean delivery, preventing preterm labor, or controlling the timing of parturition by administering a chemical compound, such as a muscarinic receptor antagonist preferably a M, receptor antagonist, or a β-3 adrenergic agonist. Also described are methods for treating preterm labor, stopping labor preparatory to Cesarean delivers', preventing preterm labor, or controlling the timing of parturition by administering an effective amount of transdermal stimulation, posterior tibial nerve stimulation or another form of non-invasive or invasive neuromodulation, unstimulated or stimulated acupuncture, magnetic field therapy, or vibratory stimulation. These methods may be practiced individually, in combination with each other, or in combination with known tocolytic methods or medications.

The present disclosure is directed to methods for treating diseases for which cysteamine is indicated and compounds useful in such methods.

The present disclosure is directed to methods for treating diseases for which cysteamine is indicated and compounds useful in such methods.

Provided herein are deuterated RUC-4 compounds, and related compositions and therapeutic methods.

Provided herein are deuterated RUC-4 compounds, and related compositions and therapeutic methods.

The present invention provides using a substituted 1-arylalkyl-4-acylaminopiperidine compound of Formula I: ##STR00001##
to treat various clinical conditions including, but not limited to, hemorrhagic shock, nicotine withdrawal symptoms, gastrointestinal side effects of opioids, cancer therapy, epithelial wounds, herpes zoster infection, or opioid-induced pruritus. In compound of Formula I, R.sup.1 is C.sub.1-10 alkyl, C.sub.1-10 haloalkyl, optionally substituted aryl, or optionally substituted heteroaryl; R.sup.2 is C.sub.1-6 alkylene; Y is optionally substituted aryl, optionally substituted heteroaryl, or a moiety of the formula —C(═O)—X.sup.1, wherein X.sup.1 is —OR.sup.3 or —NR.sup.4R.sup.5, where each of R.sup.3, R.sup.4 and R.sup.5 is H or C.sub.1-10 alkyl.